Our results are in line with a previous clinical correlation study showed that IFN activity was associated with a low risk in patients with HER2-positive breast cancer (Callari et al., 2014) In addition, IFN could act as a regulatory factor against HER2-positive cancers (Stagg et al., 2011; Castiello et al., 2018). This evidence concerns the gene ERBB2 and cancer.